SAFINAMIDE: EVALUATION OF EFFICACY IN RELIEF OF PARKINSON'S DISEASE SYMPTOMS

Abstract

This study aimed to describe the efficacy of safinamide (Xadago) in the treatment of Parkinson's disease (PD), considering its effects on motor and non-motor symptoms. This is a narrative, descriptive, and exploratory literature review conducted on Google Scholar between April and May 2025, using the descriptors "safinamide," "signs," "symptoms," "Parkinson's disease," and "mechanism of action," combined by the Boolean operator AND. The inclusion criteria were articles in Portuguese, free of charge, and published between 2013 and 2023, resulting in the selection of 18 studies for analysis. The results demonstrated that safinamide, as a selective and reversible MAO-B inhibitor, combined with modulation of glutamate release, significantly contributed to the control of motor fluctuations and pain reduction in patients with PD, without increasing dyskinesias. The studies analyzed showed improvements in pain assessment scales, quality of life, and motor symptoms when used in combination with Levodopa. The conclusion is that Safinamide is an effective and safe therapeutic alternative for the symptomatic management of PD, promoting a better quality of life for patients. The crucial role of nursing in monitoring, adherence, and responses to this therapy is also highlighted.